AI重构医疗，从场景落地到变现讨论 ——AI医疗行业专题报告 2026年1月22日 分析师：吴佳青，执业证书编号：S0930519120001 证券研究报告 目录 CONTENT S 第一章：复盘 •本轮行情与上轮行情的异同 第二章：AI+药物研发 •靶点发现与验证 •变现模式探讨：看好 CRO+Biotech 第四章：AI+诊疗 •环境智能与自动病历生成 •大模型驱动的 AI医生助手 第五章：AI手术机器人&健康管理 • AI在手术机器人领域的应用 可穿戴设备与数字疗法 • 第三章：AI+医学影像 •从 辅助诊断迈向全流程赋能 2025年初国内外AI医疗概念股普涨，美股AI医疗行情更侧重于健康管理、AI数字化临床实验领域，国内有相关概念映射标的 涨幅较大 1）健康管理服务：商业模式以订阅制为主，提供AI智能问诊、AI私人医生等服务，制定针对患者的个性化健康管理方案。 2）AI数字化临床实验：提供药物研发和医疗信息服务，在临床试验中运用AI技术进行数据管理、患者招募和疗效评估等。 •变现模式探讨 第六章：投资建议 第七章：风险分析 请务必参阅正文之后的重要声明 2 26年初国内AI医疗概念股普涨，行情发酵侧重 ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Core Viewpoint - The announcements from Pag Biotech-B (02625) reflect a dual approach of "confidence" and "aggression," with cornerstone shareholders extending their lock-up period to express long-term confidence, while simultaneously initiating a placement to raise funds for future growth [1][2]. Group 1: Cornerstone Shareholder Lock-Up - Cornerstone investors have voluntarily extended their lock-up period for the second time, now until April 30, 2024, indicating strong confidence in the company's R&D capabilities and progress towards significant clinical milestones [2]. - This extension signifies that cornerstone investors are not merely financial speculators but are committed industry capital or long-term value investors, willing to sacrifice liquidity to support the company's growth [2]. - The timing of the lock-up extension suggests it may coincide with key R&D milestones or potential international collaborations, reflecting the investors' expectations for positive developments [2]. Group 2: Fundraising Strategy - Pag Biotech plans to raise nearly HKD 300 million through a placement at HKD 58.41 per share, with several well-known institutions acting as joint placement agents [3]. - The funds are earmarked for strategic development rather than immediate financial relief, with a focus on four key areas: digital transformation in R&D, financial health, pipeline sustainability and internationalization, and operational reserves [3][4]. - The first area, digital transformation, will consume HKD 118 million (40% of the total), focusing on building an AI drug discovery platform, a unified database for competitive analysis, and a digital patient platform to enhance drug adherence and collect real-world data [3][4]. Group 3: Financial Health and International Expansion - The second area, financial health, will account for 28% of the funds, aimed at repaying bank loans to reduce interest expenses and optimize financial statements, thereby enhancing the company's resilience during industry downturns [4]. - The third area focuses on ensuring the continuous development of pipeline products PB2301/PB2309 and establishing a subsidiary in Hong Kong to facilitate global expansion, indicating a proactive approach to international collaboration opportunities [4][5]. - The final area, operational reserves, will utilize 10% of the funds to prepare for the upcoming commercialization phase, ensuring the company is well-equipped for future market challenges [5]. Group 4: Overall Strategic Vision - The combination of the fundraising initiative and the cornerstone investors' support creates a synergistic effect, reducing uncertainties associated with the placement and shifting market focus from short-term dilution to long-term value creation [7]. - This strategic approach indicates that the management is not only focused on immediate clinical data but is also considering systematic improvements in overall innovation efficiency and global competitiveness [6].

Core Viewpoint - The announcements from Paig Bio-B (02625) reflect a dual approach of "confidence" and "aggressiveness," with cornerstone shareholders voluntarily locking their shares to express long-term confidence in the company's development while also initiating a placement to raise funds for future expansion [1][2]. Group 1: Cornerstone Shareholder Lock-up - Cornerstone investors have voluntarily extended their share lock-up period to April 30, 2024, demonstrating their strong confidence in the company's R&D capabilities and progress towards significant clinical milestones [2]. - This extension indicates that cornerstone investors are not merely financial speculators but rather long-term value investors, willing to forgo liquidity to support the company's growth [2]. - The timing of the lock-up extension suggests it may coincide with key R&D milestones or potential international collaborations, reflecting the investors' expectations for positive developments [2]. Group 2: Fundraising Strategy - Paig Bio plans to raise nearly HKD 300 million through a share placement at HKD 58.41 per share, with the offering managed by several prominent institutions [3]. - The funds are earmarked for strategic development rather than immediate financial relief, with a focus on four key areas: digital transformation in R&D, financial health, pipeline sustainability, and operational reserves [3][4]. - The first area, digital transformation, will consume HKD 118 million (40% of the total), aimed at enhancing drug discovery through AI and data integration [3][4]. Group 3: Financial Health and Pipeline Development - The second area focuses on financial health, allocating 28% of the funds to repay bank loans, thereby reducing interest expenses and improving cash flow [4]. - The third area emphasizes pipeline sustainability and internationalization, with 12% and 10% of the funds respectively directed towards advancing products PB2301/PB2309 and establishing a subsidiary in Hong Kong for global expansion [4][5]. - The final area, operational reserves, will account for 10% of the funds, preparing the company for the upcoming commercialization phase [5]. Group 4: Market Perception and Future Outlook - The combination of the fundraising initiative and the cornerstone investors' support creates a positive feedback loop, reducing uncertainties associated with the placement and shifting market focus from short-term dilution to long-term value creation [6]. - The management's proactive approach, coupled with the backing from cornerstone investors, positions Paig Bio favorably for future growth and innovation, making it a company to watch in the industry [6].

Core Viewpoint - The control transfer of *ST Sailong has been finalized, leading to a new board of directors and management team, which is expected to enhance the company's innovation capabilities and market competitiveness through substantial financial support and industry resources from the new controlling shareholder [1][4]. Group 1: Management Changes - The announcement on August 10 revealed the resignation of several key executives, including Chairman and President Cai Nanguai, and the election of new non-independent directors, including Jia Jinbin and Chen Ke, with Chen Ke appointed as the new president [1][2]. - The new board members bring diverse backgrounds in medicine, finance, and investment, which is anticipated to improve the company's governance and strategic direction [3][4]. Group 2: New Controlling Shareholder - The new controlling shareholder, Hainan Yayi, acquired a 14.16% stake from previous shareholders Cai Nanguai and Tang Lin, who have committed to relinquishing certain shareholder rights [6][7]. - Hainan Yayi's investment structure includes significant contributions from notable partners, including Chen Zhansheng, who has a strong background in various industries, including pharmaceuticals and finance [7]. Group 3: Strategic Investments - Hainan Yayi has a history of investing in AI drug development companies, which aligns with *ST Sailong's strategic focus on innovation in drug research and development [5][8]. - The partnership with investment firms like Tian Tu Investment and Jing Tai Technology for strategic investments in AI drug discovery platforms is expected to enhance *ST Sailong's capabilities in this area [8].

Group 1 - The core point of the news is that JingTai Holdings (02228.HK) experienced a significant stock price increase of 8.48% due to its subsidiary JingTai Technology securing a record-breaking order in the AI and robotics drug development sector [2] - JingTai Technology announced a pipeline cooperation agreement with DoveTree, with a total order value of approximately HKD 47 billion (USD 5.99 billion), and has received an initial payment of about HKD 400 million (USD 51 million) [2] - The agreement involves collaboration on several preclinical stage large and small molecule innovative drug assets, with DoveTree holding exclusive global development and commercialization rights [2] Group 2 - In addition to the initial payment, JingTai Technology is entitled to receive further payments of approximately HKD 385 million (USD 49 million) and potential milestone payments and sales shares amounting to about HKD 462 billion (USD 58.9 billion) [2] - The collaboration will focus on high-potential pipeline projects in oncology, immunology and inflammation diseases, neurological disorders, and metabolic disorders [2] - The emergence of AI technology in drug development aims to reduce the typical 10-15 year timeline and the USD 1-1.5 billion investment required, while improving success rates [3] Group 3 - The AI pharmaceutical sector is undergoing rapid iteration and transformation, supported by algorithm updates and computational power [3] - There is a renewed interest in AI technology within the capital and pharmaceutical sectors, exemplified by a strategic research cooperation agreement between Shijiazhuang Pharmaceutical Group and AstraZeneca [3] - For AI pharmaceutical companies, achieving a commercial closed loop is crucial, with business models focusing on software sales, external licensing, and independent drug development [3] Group 4 - In 2024, JingTai Holdings is projected to achieve revenue of HKD 266 million, although the adjusted net loss (non-IFRS measure) is expected to remain high at HKD 455 million, representing a 12.5% reduction compared to the losses in 2023 [3]

Core Insights - PwC's report highlights China's unique "new quality productivity" competitive advantage, driven by technological upgrades and innovative decision-making, which presents structural growth opportunities for global investors [1][2] Group 1: Rise of New Quality Productivity - The global economic adjustment period has prompted 42% of surveyed CEOs to believe that current business models may not survive the next decade, showcasing the need for systemic breakthroughs in productivity [2] - China is transitioning from a demographic dividend to a talent dividend, with software developers constituting one-third of the global total and over 5 million STEM graduates annually, enhancing its talent pool [2] - The "technology middle platform" strategy adopted by Chinese enterprises allows for rapid industrialization of business data, facilitating quick application of new technologies across various sectors [2] Group 2: Digital Infrastructure and Market Dynamics - China's robust digital infrastructure supports rapid intelligent transformation across the entire industry chain, benefiting businesses of all sizes and enhancing production efficiency [2] - Chinese companies are reportedly gaining greater benefits from generative AI compared to their global counterparts, indicating a shift from low-cost labor to high-resilience digital solutions [2] - The Chinese consumer market is evolving from scale advantages to global decision-making leadership, with 76% of respondents willing to pay a premium for eco-friendly products, surpassing figures in the US and Europe [3] Group 3: Investment Opportunities in Economic Development - China's GDP growth rate is projected to reach 5% in 2024, with significant investment opportunities in consumption upgrades, industrial integration, and green transformation [4] - The youth market, lower-tier market activation, and the demand upgrade from high-net-worth individuals are identified as key drivers of consumption potential [4] - The integration of biotechnology and information technology is creating new opportunities in various sectors, with the low-altitude economy and satellite internet services expected to exceed a market scale of 100 billion [4] Group 4: Recommendations for Multinational Enterprises - Multinational companies are encouraged to optimize their positioning in the Chinese market by establishing a new strategy focused on "innovation symbiosis and value sharing" [5] - Companies should build localized innovation ecosystems through local R&D centers and government collaborations, creating a framework that combines Chinese R&D with global adaptation [5] - A resilient management framework is recommended, including a dual empowerment assessment system to quantify the benefits of collaboration within the Chinese business ecosystem [5]